Search Browse Earnings

DYNAVAX TECHNOLOGIES CORP

Nasdaq:DVAX

Pharmaceutical Preparations·EMERYVILLE, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$722.7M

+64.5% YoY

FY 2024

Adj. EBITDA

$287.3M

39.8% margin

FY 2024

Net Income

$293.2M

40.6% margin

FY 2024

EPS (Diluted)

$1.97

FY 2024

Stock Price

$15.50

+0.0%

2026-02-09

52W Range

$9.20 – $15.73

P/E Ratio

7.9x

Market Cap

$1.8B

Cash

$202.0M

FY 2024

Total Debt

$192.6M

FY 2021

Net Cash

$9.4M

FY 2021

Enterprise Value

$1.8B

Debt / EBITDA

-0.0x

FY 2024

EV / EBITDA

6.3x

Employees

—